Treatment AI Poised to Revolutionize Global Healthcare, Slashing Costs and Elevating Patient Care Worldwide
Upside of Investing in AI
The Next Industrial Revolution is Powered by Artificial Intelligence
The next industrial revolution is here, driven by the transformative power of Artificial Intelligence (AI). This technology is reshaping industries, creating unprecedented opportunities, and redefining possibilities. Ignoring the AI revolution would be a grave oversight for investors.
NVIDIA has led this charge, with its stock soaring nearly 3,000% in recent years, becoming the world’s most valuable publicly traded company. A $1,000 investment in NVIDIA a decade ago would now be worth an astonishing $297,605.
However, for those seeking significant returns, industry giants like NVIDIA and Microsoft might not suffice.
Enter Treatment AI (OTC: TREIF | CSE: TRUE) – a nimble, innovative company at the intersection of AI and healthcare. Treatment AI offers exposure to the AI revolution and presents a fantastic opportunity for investors looking for a high-torque play in this dynamic space.
AI has been revolutionizing industries globally, yet healthcare has lagged in adoption. This sector is now at a critical juncture, with outdated systems failing to meet the needs of providers and patients alike.
Accessibility remains a significant issue, with healthcare costs prohibitive for many, even in well-developed regions. The reliance on unreliable tools like Google or WebMD highlights the urgent need for innovative solutions.
The healthcare industry is ripe for disruption, and AI is poised to lead this transformation, making quality care accessible and efficient for all.
"It's hard to imagine a better use of AIs than saving the lives of children,"
The Unstoppable Rise of eHealth Stocks
While these stocks have had impressive runs, some have pulled back post-Covid, often due to offering only basic services like general practice video calls.
Why are Investors looking towards Treatment AI's Comprehensive Medical Database?
Treatment AI (OTC: TREIF | CSE: TRUE) is revolutionizing healthcare with its advanced AI engine designed to diagnose patient ailments accurately and efficiently. The software guides users through identifying pain, specifying symptoms, reporting exposure and history, and receiving diagnostic results.
Unlike generative models like ChatGPT, TRUE’s AI is fact-based and non-contaminable, drawing from the proprietary Global Library of Medicine, which includes data on over 1,000 diseases and 10,000 symptoms, built with ~$10M investment and input from hundreds of doctors.
TRUE’s AI was rigorously tested by allowing an undergraduate non-medical student to take the OSCE exam—a medical school graduation requirement in 57 countries—using the software. The student achieved a 92% success rate, accurately diagnosing the “most likely” condition in 11 out of 12 complex scenarios, and the “second most likely” in the 12th. This underscores the system’s exceptional accuracy and reliability.
The Market Opportunity for Treatment AI
Treatment ENT: Elevating Enterprise Healthcare
Treatment AI’s (OTC: TREIF | CSE: TRUE) ENT segment leverages the Global Library of Medicine (GLM) to enhance clinical support for healthcare enterprises. Applications include electronic medical records, health bots, virtual health services, medical call centers, and national triage services. Benefits for enterprises are substantial:
- Enhanced diagnostic support
- Seamless integration with existing systems
- Increased patient interaction time
- Reduced administrative costs
- Improved security and new revenue streams
With over 6,100 hospitals and 1.1 million physicians in the US alone, the global potential is immense.
Treatment MES: Transforming Medical Education
Treatment AI’s MES platform optimizes national exam processes for medical and nursing schools, reducing time, costs, and administrative burdens. Key benefits include:
- Consistent case testing and scoring
- Remedial guidance
- Enhanced PR and intake
Students gain valuable practice, continuous feedback, and 24/7 access to a reliable learning platform. The US hosts over 300 medical schools and 900 nursing schools, highlighting the vast market potential.
Strong Partnerships and Promising Pipeline
Treatment AI (OTC: TREIF | CSE: TRUE) boasts several strategic partnerships and a robust pipeline of over 50 potential customers, indicating strong market interest in their technology. Notably, partnerships with the prestigious Mayo Clinic and the University of Minnesota Medical School could lead to significant contracts.
A recent collaboration with the AI tool marketplace aiXplain allows Treatment AI to claim 80% of the revenues, marking their software as the first healthcare solution on the platform. Additionally, their partnership with Novus Health exposes their software to 1.5 million members and their families, expanding their reach significantly.
Future Valuations:
Treatment AI's Bright Prospects
Treatment AI (OTC: TREIF | CSE: TRUE) stands out in the Canadian public market, with few peers comparable to its innovative approach. HealWELL AI, a similar company, has surged over 220% in 2024, demonstrating the sector’s explosive potential.
Many private players in this space are expected to go public with multi-billion dollar valuations, or become acquisition targets. Notable 2023 acquisitions include NextGen Healthcare and Viewgol, while Amazon’s acquisition of Health Navigator underscores the high value placed on companies like TRUE. A resurgence in mergers and acquisitions could significantly boost TRUE’s valuation, especially with new deals or buyer interest on the horizon.
HealWELL vs. Treatment AI:
A Market Valuation Perspective
The only comparable for Treatment AI (OTC: TREIF | CSE: TRUE) in the Canadian public market is HealWELL (TSX: AIDX). A short analysis highlights Treatment AI’s deep undervaluation.
HealWELL has a market cap of ~$384M and trades at a 16.5x EV/sales multiple based on projected 2024 revenues. Applying this multiple to Treatment AI’s projected 2024 revenues of $4.5M, we get an implied valuation of $1.98 per share, representing a 103% upside.
Looking ahead to 2025, with projected revenues of CAD$19M, the same multiple implies a valuation of CAD$6.97 per share, an 1180% upside. This analysis is conservative, not accounting for:
- All of Treatment AI’s revenues being AI-based, which command higher multiples.
- Treatment AI’s higher margins (84-95%) compared to HealWELL’s (70-80%).
Therefore, the per-share valuation should be even higher.
High-Margin SaaS Model and New Product Launches
Treatment AI (OTC: TREIF | CSE: TRUE)’s focus on software subscription revenue yields impressive profit margins between 84% and 95%. With no need to pay providers for user access, more revenue directly benefits shareholders.
The company plans to launch two new high-margin monthly SaaS products: AI Patient for educational purposes and AI Doctor in a Pocket for enterprise use. These innovative products promise rapid revenue generation, offering efficient software solutions to both current and new partners.
These developments position Treatment AI for accelerated growth and increased profitability, enhancing value for investors.
Why Treatment AI is Set for Explosive Growth
Treatment AI (OTC: TREIF | CSE: TRUE) is poised to revolutionize healthcare with its groundbreaking AI technology, tackling critical diagnostic challenges with reliable, fact-based solutions. Their comprehensive medical database and proven diagnostic accuracy highlight their immense potential.
With robust partnerships and a focus on high-margin, subscription-based revenue, Treatment AI is set for sustainable growth. The dual emphasis on enterprise and educational sectors unlocks vast market opportunities, making it a compelling investment choice.
As AI propels industry advancements, Treatment AI stands as a healthcare innovation leader. For investors seeking significant returns and a stake in the future of healthcare, Treatment AI offers a promising opportunity.
Disclosure & Disclaimer
The publisher of this report was compensated by Torque Capital Partners for the publication of this and other reports regarding the Issuer. The purpose of this compensation was to cover the author’s time, research, and expertise in analyzing the company. It is important to note that the payment received may create a potential conflict of interest, as the author may be influenced by the compensation received. Readers are advised to consider this disclosure when evaluating the credibility and objectivity of the information provided in the article. The author owns shares in the Issuer and, from time to time, may purchase or sell additional securities.
The information contained in this article is not intended to induce the sale of a security. You should not rely on the information herein as investment advice. The Creator is a marketing and advertising company, and is not registered to act as a broker, dealer, investment adviser or in any similar capacity in any jurisdiction. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on the information on www.aistocktip.com. This Promotional Activity is intended to highlight the Client for your further investigation; this Promotional Activity is not a recommendation. Please do your own research before investing, including reading the Client’s SEDAR+ filings, news releases, and risk disclosures. Information in this Promotional Activity was provided by the Client, extracted from the Client’s website’s website and/or SEDAR+, and/or extracted from other publicly available sources.
This disclosure is intended to provide transparency and assist readers in understanding the context in which the article was written. From time to time, the author of this report, the publisher, and the publisher’s directors, officers, and other insiders may purchase or sell securities of the Issuer.
Our forecast and predictions are predicated on the current management being able to execute and achieve results we assumed in our potential future valuation. Such execution may include continued sales growth, new partnership deals, continued competitive advantage via global patent, control over manufacturing costs and generally stable economic global environment. Should any of those factors change for worse adversely affect the company’s performance, there is a risk that the potential future valuation may not be achieved.
For More Stock Alerts Sign Up Now
JOIN THE CLUB
|
This is the official website of AI Stock Tip (“AI Stock Tip” or the “Creator”).
Please read the following terms and conditions of website use (the “terms and conditions”) carefully
before accessing or using the Creator’s website as they represent a binding agreement between you
(either an individual or a single entity) and the Creator and govern your use of
www.aistocktip.com together with all of the information and materials available on such website
(collectively, “This Site” or “www.aistocktip.com”). By accessing, browsing or using This Site, you
agree to be bound by the terms and conditions as outlined herein. If you have not read, do not
understand, or do not agree to be bound by these terms and conditions, please do not use This Site.
The Creator reserves the right to change these terms and conditions from time to time at its sole
discretion and without notice.
It is your responsibility to check for any updates, and you should revisit this page from time to time as
your use of This Site is subject to the most current version of the terms and conditions posted at the
time of such use.
The Creator has taken all reasonable care in producing and publishing information contained on This
Site and will endeavour to do so regularly. However, material on This Site may still contain technical or
other inaccuracies, omissions, or typographical errors, for which the Creator assumes no responsibility.
Under no circumstances shall the Creator be liable for any direct, indirect, special, incidental,
consequential or other damages, including but not limited to, loss of programs, loss of data, loss of use
of computer or other systems, or loss of profits, whether or not advised of the possibility of damage
arising from your use, or inability to use, the material on This Site. Further, you may not modify or
reproduce in any form, electronic or otherwise, any information on This Site.
Your rights to use This Site
Provided that you accept and comply with these terms and conditions, you have the limited right to
access and use This Site to view the various materials, including information, documents and other
content on This Site and to copy, download or print a single copy of any of the information and
materials available on it, solely for your personal non-commercial use or your internal informational
use in business and not for resale or distribution to anyone else, provided that you reproduce all of the
Creator’s proprietary markings on each copy of reproduced material. Except as expressly permitted by
the Creator in writing, you may not copy, reproduce, download, upload, post, transmit, translate,
modify, distribute, sell, rent, license, transfer, mirror, frame or create derivative works from This Site, in
whole or in part, in any form or by any means.
Do Not Use Any Information in Our Publications to Make an Investment Decision
We are paid advertisers and we are publishers of publicly disseminated information on behalf of our
clients, publicly traded companies, or non-affiliate third party shareholders of various issuers (“Client
Companies”). Do not base an investment decision on any of the contents of our publications on This
Site.
We are not registered as and we do not act, directly or indirectly, in the capacity of any of the following
and you should not construe our activities as involving advice from any of the following: (a) an investment advisor; (b) a broker dealer; (c) a broker; (d) a dealer; (e) a stock recommender; (f) a stock picker; (g) a finder; (h) a securities trading expert; (i) a financial planner; (j) a securities analyst; or (k) a financial analyst.
The information found on This Site was prepared without regard to any particular investor’s investment
objectives, financial situation, or financial or investment needs. Accordingly, investors should not act on
any information contained on This Site without obtaining specific advice from their financial advisors
and should not rely on information herein as the basis for their investment decisions. Investments
based on the information provided on www.aistocktip.com involve a substantial risk of loss and
are not appropriate for everyone. No representation is being made that utilizing the information on
www.aistocktip.com will result in profitable trading or be free of risk of loss. Before deciding to
trade or invest you should carefully consider your investment objectives, level of experience, and ability
to tolerate risk. The possibility exists that you could sustain a loss of some or all of your investment.
Forward-Looking Information
Certain information contained on www.aistocktip.com, including any information as to the future
financial or operating performance of the Client Companies highlighted, may be deemed “forward
looking”. All statements on www.aistocktip.com, other than statements of historical fact, which
address events or developments is expected to occur, are “forward-looking statements” or
“forward-looking information”. Generally, these forward-looking statements can be identified by the
use of forward-looking terminology, including but not limited to, the words “expects”, “does not
expect”, “plans”, “anticipates”, “does not anticipate”, “believes”, “intends”, “estimates”, “projects”,
“potential”, “scheduled”, “forecast”, “budget” and similar expressions or their negative connotations,
or that events or conditions “will”, “would”, “may”, “could”, “should” or “might” occur.
All such forward-looking statements are subject to important risk factors and uncertainties, many of
which are beyond the ability to control or predict. Forward-looking statements are necessarily based on
estimates and assumptions that are inherently subject to known and unknown risks, uncertainties and
other factors that may cause Client Companies’ actual results, level of activity, performance or
achievements to be materially different from those expressed or implied by such forward-looking
Statements.
Forward-looking statements are not guarantees of future performance, and actual results and future
events could materially differ from those anticipated in such statements. All of the forward-looking
statements contained on www.aistocktip.com are qualified by these cautionary statements. The
Creator expressly disclaims any intent or obligation to update or revise any forward-looking statements,
whether as a result of new information, events or otherwise, except in accordance with applicable
securities laws.
Indemnity
To the maximum extent permitted by applicable law, you will defend, indemnify and hold harmless the
Creator, and its respective directors, officers, employees, consultants and agents from and against all
claims, liability, and expenses, including all legal fees and costs, arising out of your breach of any
provision of these terms and conditions or, any applicable law or proprietary or privacy right in
connection therewith. The Creator reserves the right, in its sole discretion and at its own expense, to
assume the exclusive defence and control of any matter otherwise subject to indemnification by you.
You will co-operate as fully as reasonably required in the defence of any claim.
Stock Quotes
All stock price quotes and historical stock price data on This Site are provided by third parties, are for
informational purposes only, and are not intended for trading purposes. If you are contemplating
trading in securities of companies mentioned on www.aistocktip.com, the Creator strongly advises
that you obtain independent professional advice (including independent legal and financial advice from
qualified advisors) before making any investment decision. The Creator makes no representation or
warranty regarding the timeliness, accuracy or completeness of any stock price quotes or historical
stock price data.
Laws
This Site (excluding linked sites) is controlled by the Creator from its offices within the Province of
British Columbia, Canada. By accessing This Site, you and the Creator agree that all matters relating to
your access to, or use of, This Site shall be governed by the statutes and laws of the Province of British
Columbia or the federal laws of Canada, as applicable, without regard to the conflicts of laws principles
thereof. You and the Creator also agree and hereby submit to the exclusive personal jurisdiction and
venue of the courts of the Province of British Columbia with respect to any and all matters arising in
connection with these terms and conditions.
Third Party Links
The Creator has provided links from This Site to several other websites (“Third Party Websites”) that
are arm’s-length to the Creator, and may embed content from Third Party Websites on This Site. The
viewer should be aware that in linking to Third Party Websites they are leaving This Site and the Creator
is not responsible for the content of any Third Party Website. Information on Third Party Websites, and
any information from Third party Websites embedded on This Site, may be updated, revised, or
otherwise modified without the knowledge or involvement of the Creator. The Creator expressly
disclaims any and all responsible for the accuracy of the content on any Third Party Websites, whether
on This Site or not.
|
